Back to top

Balancing Optimism and Caution: Hold Rating for Myriad Genetics Amid Strategic Shifts and Uncertainties

Leerink Partners analyst Puneet Souda has maintained their neutral stance on MYGN stock, giving a Hold rating on May 20. Puneet Souda’s rating is b...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Myriad Genetics, Inc. (MYGN)